The 4-quinolone antibacterial agents have been under development and in use for over 25 years, but despite an enormous body of research work there are still many basic questions that remain unanswered. For example, we do not know how these agents kill susceptible cells - or even how the drugs interact with the target mol- ecule(s). However, we do know that the 4-quinolones display many properties which are not shared with any other group of antibacterial agents. This book raises the unanswered questions and assesses the potential significance to future chemotherapy of their unique features. The book also raises matters which are significant for physicians as well as for the pharmaceutical industry and the assessment of these agents by legislative bodies concerned with drug safety.

Quinolones remain the most important class of antimicrobial agents discovered in recent years – over 1000 have been synthesized and evaluated. Since the publication of the original edition, considerable strides have been made in the research on structure–activity relationships, mechanism of action, resistance, pharmacodynamics and drug interactions. This edition consolidates and substantially updates our current state of knowledge of quinolones, with thirteen new chapters having been added.

It has been over 30 years since the first clinically important member of the quinolone class, nalidixic acid, was introduced into medical practice. The modification produced in the quinolone nucleus by introducing a fluorine at the 6-position led to the discovery of the newer fluoroquinolones with enhanced antibacterial activities as compared to nalidixic acid. By now a great deal of preclinical and clinical experience has been obtained with these agents. The intense interest in this class of antibacterial agents by chemists, micro biologists, toxicologists, pharmacologists, clinical pharmacologists, and clini cians in various disciplines encouraged us to summarize the information on the history, chemistry, mode of action and in vitro properties, kinetics and efficacy in animals, mechanisms of resistance, toxicity, clinical pharmacology, clinical experience, and future prospects in one volume of the Handbook of Experimental Pharmacology. As this series deals predominantly with "experimental" characteristics of drugs, our volume is dedicated specifically to quinolones and emphasizes principally their preclinical and clinical phar macological characteristics, despite the existence of several summaries on quinolones. The chemistry of the quinolones is described in detail. The chapter on the mode of action of quinolones reports the conclusive evidence that gyrase is the intracellular target of the quinolones; however, another enzyme, topoisomerase IV, may also be a target for quinolones, and the exact mechanisms by which quinolones act bactericidally are far from being understood.

Antimicrobial Agents and Intracellular Pathogens is the first book devoted to the relationships among intracellular pathogens, antibiotics, and cells. The book is divided into two sections. Part One describes the effects of antibiotics on uninfected and infected phagocytic cells, the subcellular location of antibiotic compounds, the subcellular compartment of intracellular microorganisms multiplication, and the vectorization of antibiotics. Part Two focuses on intracellular pathogens used as paradigms, including strict intracellular bacteria and antibiotics such as Chlamydia, Rickettsia, Ehrlichia, and Coxiella burnetii; facultative intracellular bacteria and antibiotics such as Legionella and Mycobacteria; and intracellular protozoa and antimicrobial agents, such as Leishmania, Trypnonosoma, and Toxoplasma. This book will be an important reference for microbiologists, clinical microbiologists, infectious disease experts, and researchers in pharmaceutical companies involved in antibiotic development.

The Quinolones covers reviews on the history, chemistry and mechanism of action, in vitro properties, pharmacokinetics, clinical overview, toxicity, adverse effects and drug interactions, and future prospects of the 4-quinolones. The book discusses the microbiology of quinolones, particularly with consideration of the development of resistance, pharmacology, toxicology, and clinical uses. Chemists, microbiologists, pharmacologists and clinicians will find the book useful.

The is the third edition of a text that surveys the drugs used to treat bacterial, fungal, prarsitic, and viral infections. This book contains comprehensive presentations of the mechanisms for both the antimicrobial actions and for the adverse clinical effects of these drugs. Complete discussions of the pharmacology are highlighted by numerous charts and tables summarizing each drug's pharmacokinetic properties and microbial susceptibility. With 3500 reference citations, The Anitmicrobial Drugs provides a complete entry into the literature, making it an invaluable resource for infectious disease specialists, clinical pharmacists, clinical microbiologists, medical students, pharmacy students, and graduate students in pharmacology and microbiology.

Surveys the newest members of a family of antimicrobial drugs increasingly being used to treat infections of the urinary tract, lungs, skin, bones, and diarrheal diseases. The drugs have been developed only since the 1960s, and still pose many questions about resistance and toxic and developmental s

Kucers’ The Use of Antibiotics is the definitive, internationally-authored reference, providing everything that the infectious diseases specialist and prescriber needs to know about antimicrobials in this vast and rapidly developing field. The much-expanded Seventh Edition comprises 4800 pages in 3 volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into four sections - antibiotics, anti-fungal drugs, anti-parasitic drugs, and anti-viral drugs - and is highly structured for ease of reference. Each chapter is organized in a consistent format, covering susceptibility, formulations and dosing (adult and pediatric), pharmacokinetics and pharmacodynamics, toxicity, and drug distribution, with detailed discussion regarding clinical uses - a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with expert contributors representing Europe, Africa, Asia, Australia, South America, the US, and Canada, the Seventh Edition adopts a truly global approach. It remains invaluable for anyone using antimicrobial agents in their clinical practice and provides, in a systematic and concise manner, all the information required when prescribing an antimicrobial to treat infection.

After thirty five years, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. John E. Bennett and Raphael Dolin along with new editorial team member Dr. Martin Blaser have meticulously updated this latest edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition helps you identify and treat whatever infectious disease you see. Get the answers to any questions you have with more in-depth coverage of epidemiology, etiology, pathology, microbiology, immunology, and treatment of infectious agents than you’ll find in any other ID resource. Apply the latest knowledge with updated diagnoses and treatments for currently recognized and newly emerging infectious diseases, such as those caused by avian and swine influenza viruses. Put the latest knowledge to work in your practice with new or completely revised chapters on Influenza (new pandemic strains); New Middle East Respiratory Syndrome (MERS) Virus; Probiotics; Antibiotics for resistant bacteria; Antifungal drugs; New Antivirals for hepatitis B and C; Clostridium difficile treatment; Sepsis; Advances in HIV prevention and treatment; Viral gastroenteritis; Lyme Disease; Helicobacter pylori; Malaria; Infections in immunocompromised hosts; Immunization (new vaccines and new recommendations); and Microbiome. Benefit from fresh perspectives and expanded global insights from an expanded team of American and International contributors. Martin Blaser, MD, a leading expert and Muriel G. and George W. Singer Professional of Translational Medicine at New York University School of Medicine, joins veteran PPID editors John E. Bennett, MD, and Raphael Dolin, MD to continue a legacy of excellence. Find and grasp the information you need easily and rapidly with newly added chapter summaries.